significant interaction has just been identified between gemfibrozil (Lopid, etc) and repaglinide (Prandin)

June 2003

A significant interaction has just been identified between gemfibrozil (Lopid, etc) and repaglinide (Prandin).

These drugs are likely to be used together. Many diabetes patients get gemfibrozil to lower triglycerides and increase HDL.

Now there's evidence that gemfibrozil can inhibit a cytochrome P450 enzyme that metabolizes repaglinide.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote